MediWound Unveils EscharEx Data Showing Advantages Over Competitor
Event summary
- MediWound will present new EscharEx data at three major wound care conferences in April and May 2026.
- Preclinical studies show EscharEx outperforms SANTYL in debridement and activates wound-healing pathways.
- Phase III VALUE study in venous leg ulcers (VLUs) is ongoing, with planned expansion into diabetic foot ulcers (DFUs) and pressure ulcers in H2 2026.
- Post-hoc analysis from ChronEx Phase II trial supports co-primary endpoint of VALUE Phase III study.
The big picture
MediWound’s presentation of new EscharEx data at leading wound care conferences underscores its strategic push to establish the therapy as a new standard in chronic wound management. The company’s focus on expanding into diabetic foot ulcers and pressure ulcers aligns with the growing demand for effective, non-surgical debridement solutions. The ongoing Phase III VALUE study and planned trials in H2 2026 position MediWound to capture a substantial share of the global wound care market.
What we're watching
- Clinical Validation
- Whether EscharEx’s mechanism of action and comparative advantages over SANTYL will accelerate regulatory approval and market adoption.
- Market Expansion
- The pace at which MediWound can expand EscharEx into diabetic foot ulcers (DFUs) and pressure ulcers following the ongoing Phase III study.
- Competitive Positioning
- How MediWound’s bromelain-based enzymatic therapy will differentiate itself in the chronic wound management market.
Related topics